The evaluation of the efficacy of adalimumab in refractory non-infectious uveitis with ultra-widefield fundus fluorescein angiography


Creative Commons License

UZLU D. , Kose B., AKYOL N. , ERDÖL H. , GÜNAY M.

INTERNATIONAL OPHTHALMOLOGY, 2022 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Publication Date: 2022
  • Doi Number: 10.1007/s10792-021-02209-x
  • Title of Journal : INTERNATIONAL OPHTHALMOLOGY
  • Keywords: Uveitis, Refractory uveitis, Adalimumab, Fluorescein angiography, OCT, OPTICAL COHERENCE TOMOGRAPHY, LONG-TERM EFFICACY, BEHCETS-DISEASE, TNF-ALPHA, MULTICENTER, INFLIXIMAB, CORTICOSTEROIDS, STANDARDIZATION

Abstract

Aim To investigate the efficacy of adalimumab in the cases with refractory non-infectious uveitis and evaluate retinal vascular leakage changes on ultra-widefield fundus fluorescein angiography. Methods Twenty-three patients with refractory uveitis were included in study. Results Forty-four eyes of 23 patients with non-infectious uveitiswere evaluated. Clinically active inflammation was present in 19 eyes (43.18%), while 25 (56.8%) were inactive. The mean drug burden was a 9.91 +/- 3.78 (5-21) in baseline, 7.3 +/- 4.25 at third and 8.0 +/- 4.71 at sixth month (p = 0.022). The mean choroidal thickness was 256.65 +/- 43.63 mu m in baseline, 240.49 +/- 36.73 mu m at third and 224.81 +/- 34.91 mu m at sixth month (p <= 0.05). In terms of leakage extend, leakage was initially present in a mean of 2.95 +/- 4.55 clock hours, 2.41 +/- 3.91 at third and 1.76 +/- 3.44 at sixth month (p < 0.001). Conclusion Adalimumab was found to be effective in establishing inflammation control by reducing drug burden, controlling retinal vascular leakage and choroidal inflammation in refractory uveitis.